-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Blood NfL and glial fibrillary acidic protein (GFAP) also showed strong ability to judge AD/dementia and cognitive decline
Administer FDA
Previous studies of p-tau181 in blood have had limited follow-up, but it is theorized that levels of p-tau181 may have risen more than a decade before diagnosis
diagnosis
Here, Hannah Stocker et al.
Blood vessel
They followed 768 participants (aged 50-75 years) for 17 years of baseline biomarker levels using single-molecule array technology in a community cohort
They found that: GFAP was associated with clinical AD incidence even more than ten years before diagnosis (9-17 years), whereas p-tau181 and NfL were associated with more moderate AD risk (within 9 years)
GFAP is associated with clinical AD incidence
A clear interaction was found between cardiovascular health and p-tau181/NfL
The significance of this study is the discovery that GFAP may be an early AD biomarker that increases before p-tau181 and NfL, and the effect-modulating role of cardiovascular health should be considered in biomarker risk stratification
GFAP may be an early AD biomarker that increases before p-tau181 and NfL, and the effect-modulating role of cardiovascular health should be considered in biomarker risk stratification
Original source:
Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years.
Alzheimers Dement.
Leave a comment here
